One study presented to heart doctors showed a new drug, Otsuka Pharmaceutical Co.'s tolvaptan, improved shortness of breath and other problems in patients with severe heart failure. But that study, along with one testing Johnson & Johnson's Natrecor, failed to show that either drug helped people live longer or prevented hospital stays.

Related Summaries